Fingolimod

Fingolimod is an FDA-registered drug product whose active ingredient is FINGOLIMOD. It is labelled by Novadoz Pharmaceuticals LLC taken by oral and marketed as a human prescription drug product. Identifiers on file: NDC 72205-227, application ANDA207993, label effective 20260827. It is one of 5 FDA drug label records sharing the active ingredient FINGOLIMOD. This page reproduces the FDA-approved label text so you can check what a product is, who makes it and how it is supplied before discussing it with a pharmacist or prescriber.

Across FDA labelling, products containing FINGOLIMOD are most often described in connection with: fingolimod capsules, treatment relapsing, forms multiple, sclerosis include, clinically isolated, syndrome relapsing-remitting, active secondary, progressive disease. Wording differs between labels, and the full indications section on this page takes precedence when it is present.

1 INDICATIONS AND USAGE Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod Capsules are sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )

2 DOSAGE AND ADMINISTRATION Assessments are required prior to initiating Fingolimod Capsules ( 2.1 ) Recommended dosage for adults and pediatric patients (10 years of age and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food. ( 2.2 , 2.3 ) Recommended dosage for pediatric patients (10 years of age and above) weighing less than or equal to 40 kg: 0.25 mg orally once daily, with or without food. ( 2.2 , 2.3 ). First-Dose Monitoring (including reinitiation after discontinuation greater than 14 days and dose increases): oObserve all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at end of observation period required. ( 2.4 ) oMonitor until resolution if heart rate < 45 beats per minute (bpm) in adults, < 55 bpm in patients aged 12 years and above, or < 60 bpm in pediatric patients aged 10 to below 12 years, atrioventricular (AV) block, or if lowest postdose heart rate is at the end of the observation period. ( 2.4 ) oMonitor symptomatic bradycardia with ECG until resolved. Continue overnight if intervention is required; repeat first-dose monitoring for second dose. ( 2.4 ) oObserve patients overnight if at higher risk of symptomatic bradycardia, heart block, prolonged QTc interval, or if taking drugs with known risk of torsades de pointes. ( 2.4 , 7.1 ) 2.1 Assessment Prior to Initiating Fingolimod Capsules Cardiac Evaluation Obtain a cardiac evaluation in patients with certain preexisting conditions [ see Warnings and Precautions (5.1) ] . Prior to starting treatment, determine whether patients are taking drugs that could slow heart rate or atrioventricular (AV) conduction [ see Dosage and Administration (2.4) , Drug Interactions (7.5) ] . Complete Blood Count (CBC) Review results of a recent CBC [ see Warnings and Precautions (5.2) , Drug Interactions (7.6) ] . Serum Transaminases (ALT and AST) and Total Bilirubin Levels Prior to starting treatment with Fingolimod Capsules (i.e., within 6 months), obtain serum transaminases [alanine transaminase (ALT)and aspartate transferase (AST)] and total bilirubin levels [see Warnings and Precautions (5.5) ]. Ophthalmic Assessment Obtain a baseline evaluation of the fundus, including the macula, near the start of the treatment with fingolimod capsules [see Warningsand Precautions (5.4) ]. Skin Examination Obtain a baseline skin examination prior to or shortly after initiation of fingolimod capsules. If a suspicious skin lesion is observed, itshould be promptly evaluated [see Warnings and Precautions (5.12) ]. Prior Medications If patients are taking antineoplastic, immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with Fingolimod Capsules [ see Warnings and Precautions (5.2) , Drug Interactions (7.4) ]. Vaccinations Test patients for antibodies to varicella zoster virus (VZV) before initiating Fingolimod Capsules; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with Fingolimod Capsules [ see Warnings and Precautions (5.2) ]. It is recommended that pediatric patients if possible, complete all immunizations in accordance with current immunization guidelines prior to initiating Fingolimod Capsules therapy. 2.2 Important Administration Instructions Patients who initiate Fingolimod Capsules, and those who reinitiate treatment after discontinuation for longer than 14 days, require first dose monitoring. This monitoring is also recommended when the dose is increased in pediatric patients [see Dosage and Administration (2.4 , 2.5 )]. Fingolimod Capsules can be taken with or without food. 2.3 Recommended Dosage In adults and pediatric patients 10 years of age and older weighing more than 40 kg, the recommended dosage of Fingolimod Capsules is 0.5 mg orally once daily. Fingolimod doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit. 2.4 First-Dose Monitoring Initiation of Fingolimod Capsules treatment results in a decrease in heart rate, for which monitoring is recommended [ see Warnings and Precautions (5.1) , Clinical Pharmacology (12.2) ]. Prior to dosing and at the end of the observation period, obtain an electrocardiogram (ECG) in all patients. First 6-Hour Monitoring Administer the first dose of Fingolimod Capsules in a setting in which resources to appropriately manage symptomatic bradycardia are available. Monitor all patients for 6 hours after the first dose for signs and symptoms of bradycardia with hourly pulse and blood pressure measurement. Additional Monitoring After 6-Hour Monitoring Continue monitoring until the abnormality resolves if any of the following is present (even in the absence of symptoms) after 6 hours: the heart rate 6 hours postdose is less than 45beats per minute (bpm) in adults, less than 55 bpm in pediatric patients 12 years of age and older, or less than 60 bpm in pediatric patients 10 or 11 years of age; the heart rate 6 hours postdose is at the lowest value postdose suggesting that the maximum pharmacodynamic effect on the heart may not have occurred; the ECG 6 hours postdose shows new onset second degree or higheratrioventricular (AV) block. If postdose symptomatic bradycardia occurs, initiate appropriate management, begin continuous ECG monitoring, and continue monitoring until the symptoms have resolved if no pharmacological treatment is required. If pharmacological treatment is required, continue monitoring overnight and repeat 6-hour monitoring after the second dose. Overnight Monitoring Continuous overnight ECG monitoring in a medical facility should be instituted: in patients that require pharmacologic intervention for symptomatic bradycardia. In these patients, the first-dose monitoring strategy should be repeated after the second dose of Fingolimod Capsules; in patients with some preexisting heart and cerebrovascular conditions [ see Warnings and Precautions (5.1) ]; in patients with a prolonged QTc interval before dosing or during 6-hour observation, or at additional risk for QT prolongation, or on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes [ see Warnings and Precautions (5.1) , Drug Interactions (7.1) ]; in patients receiving concurrent therapy with drugs that slow heart rate or AV conduction [ see Drug Interactions (7.5) ]. 2.5 Monitoring After Reinitiation of Therapy Following Discontinuation When restarting Fingolimod Capsules after discontinuation for more than 14 days after the first month of treatment, perform first- dose monitoring, because effects on heart rate and AV conduction may recur on reintroduction of Fingolimod Capsules treatment [ see Dosage and Administration (2.4) ]. The same precautions (first-dose monitoring) as for initial dosing are applicable. Within the first 2 weeks of treatment, first-dose procedures are recommended after interruption of 1 day or more; during Weeks 3 and 4 of treatment, first-dose procedures are recommended after treatment interruption of more than 7 days.

4 CONTRAINDICATIONS Fingolimod Capsules are contraindicated in patients who have: in the last 6 months experienced myocardial infarction, unstable angina, stroke,transient ischemic attack (TIA), decompensated heart failure requiring hospitalization or Class III/IV heart failure a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker [ see Warnings and Precautions (5.1) ] a baseline QTc interval ≥ 500 msec cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in Fingolimod Capsules. Observed reactions include rash, urticaria and angioedema upon treatment initiation [ see Warnings and Precautions (5.14) ]. Recent myocardial infarction, unstable angina, stroke, transient ischemic attack(TIA), decompensated heart failure with hospitalization, or Class III/IV heart failure. ( 4 ) History of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker. ( 4 ) Baseline QTc interval ≥500 msec. ( 4 ) Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs. ( 4 ) Hypersensitivity to fingolimod or its excipients. ( 4 )

6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in labeling: Bradyarrhythmia and Atrioventricular Blocks [ see Warnings and Precautions (5.1) ] Infections [ see Warnings and Precautions (5.2) ] Progressive Multifocal Leukoencephalopathy [ see Warnings and Precautions (5.3) ] Macular Edema [ see Warnings and Precautions (5.4) ] Liver Injury [ see Warnings and Precautions (5.5) ] Posterior Reversible Encephalopathy Syndrome [ see Warnings and Precautions (5.6) ] Respiratory Effects [ see Warnings and Precautions (5.7) ] Fetal Risk [ see Warnings and Precautions (5.8) ] Severe Increase in Disability After Stopping Fingolimod Capsules [ see Warnings and Precautions (5.9) ] Tumefactive Multiple Sclerosis [ see Warnings and Precautions (5.10) ] Increased Blood Pressure [ see Warnings and Precautions (5.11) ] Malignancies [ see Warnings and Precautions (5.12) ] Immune System Effects Following Fingolimod Capsules Discontinuation [ see Warnings and Precautions (5.13) ] Hypersensitivity Reactions [ see Warnings and Precautions (5.14)] Most common adverse reactions (incidence ≥ 10% and greater than placebo): Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adults In clinical trials (Studies 1, 2, and 3), a total of 1,212 patients with relapsing forms of multiple sclerosis received Fingolimod Capsules 0.5 mg. This included 783 patients who received Fingolimod Capsules 0.5 mg in the 2-year placebo-controlled trials (Studies 1 and 3) and 429 patients who received Fingolimod Capsules 0.5 mg in the 1-year active-controlled trial (Study 2). The overall exposure in the controlled trials was equivalent to 1,716 person-years. Approximately 1,000 patients received at least 2 years of treatment with Fingolimod Capsules 0.5 mg. In all clinical studies, including uncontrolled extension studies, the exposure to Fingolimod Capsules 0.5 mg was approximately 4,119 person-years. In placebo-controlled trials, the most frequent adverse reactions (incidence ≥10% and greater than placebo) for Fingolimod Capsules 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity. Adverse events that led to treatment discontinuation and occurred in more than 1% of patients taking Fingolimod Capsules 0.5 mg, were serum transaminase elevations (4.7% compared to 1% on placebo) and basal cell carcinoma (1% compared to 0.5% on placebo). Table 1 lists adverse reactions in clinical studies in adults that occurred in ≥ 1% of Fingolimod-treated patients and ≥ 1% higher rate than for placebo. Table 1: Adverse Reactions Reported in Adult Studies 1 and 3 (Occurring in ≥1% of Patients and Reported for Fingolimod Capsules 0.5 mg at ≥1% Higher Rate Than for Placebo) Adverse drug reactions Fingolimod Capsules 0.5 mg N=783 % Placebo N=773 % Infections Influenza 11 8 Sinusitis 11 8 Bronchitis 8 5 Herpes zoster 2 1 Tinea versicolor 2 <1 Cardiac disorders Bradycardia 3 1 Nervous system disorders Headache 25 24 Migraine 6 4 Gastrointestinal disorders Nausea 13 12 Diarrhea 13 10 Abdominal pain 11 10 General disorders and administration-site conditions Asthenia 2 1 Musculoskeletal and connective tissue disorders Back pain 10 9 Pain in extremity 10 7 Skin and subcutaneous tissue disorders Alopecia 3 2 Actinic keratosis 2 1 Investigations Liver transaminase elevations (ALT/GGT/AST) 15 4 Blood triglycerides increased 3 1 Respiratory, thoracic, and mediastinal disorders Cough 12 11 Dyspnea 9 7 Eye disorders Vision blurred 4 2 Vascular disorders Hypertension 8 4 Blood and lymphatic system disorders Lymphopenia 7 <1 Leukopenia 2 <1 Neoplasms benign, malignant, and unspecified (including cysts and polyps) Skin papilloma 3 2 Basal cell carcinoma 2 1 Abbreviations: ALT, alanine transaminase; AST, aspartate transferase; GGT, gamma-glutamyl transferase. Adverse reactions of seizure, dizziness, pneumonia, eczema, and pruritus were also reported in Studies 1 and 3, but did not meet the reporting rate criteria for inclusion in Table 1 (difference was less than 1%). Adverse reactions with Fingolimod Capsules 0.5 mg in Study 2, the 1-year active-controlled (versus interferon beta-1a) study were generally similar to those in Studies 1 and 3. Vascular Events Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received Fingolimod Capsules doses (1.25 mg to 5 mg) higher than recommended for use in MS. Similar events have been reported with Fingolimod Capsules in the postmarketing setting although a causal relationship has not been established. Seizure Cases of seizures, including status epilepticus, have been reported with the use of Fingolimod Capsules in clinical trials and in the postmarketing setting in adults [ see Adverse Reactions (6.2) ]. In adult clinical trials, the rate of seizures was 0.9% in Fingolimod-treated patients and 0.3% in placebo-treated patients. It is unknown whether these events were related to the effects of multiple sclerosis alone, to Fingolimod Capsules, or to a combination of both. Pediatric Patients 10 Years of Age and Older In the controlled pediatric trial (Study 4), the safety profile in pediatric patients receiving Fingolimod Capsules 0.25 mg or 0.5 mg daily was similar to that seen in adult patients. In the pediatric study, cases of seizures were reported in 5.6% of Fingolimod-treated patients and 0.9% of interferon beta-1a-treated patients [ see Use in Specific Populations (8.4) ]. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Fingolimod Capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders : Hemolytic anemia and thrombocytopenia Hepatobiliary Disorders: Liver injury [ see Warnings and Precautions (5.5) ] Infections: Infections, including cryptococcal infections [ see Warnings and Precautions (5.2) ] , human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer [ see Warnings and Precautions (5.2) ] , progressive multifocal leukoencephalopathy [ see Warnings and Precautions (5.3) ] Musculoskeletal and Connective Tissue Disorders: Arthralgia, myalgia Nervous System Disorders: Posterior reversible encephalopathy syndrome [ see Warnings and Precautions (5.6) ] , seizures, including status epilepticus [ see Adverse Reactions (6.1) ] Neoplasms, Benign, Malignant, and Unspecified (including cysts and polyps): Melanoma, Merkel cell carcinoma, cutaneous T-cell lymphoma (including mycosis fungoides),Kaposi’s sarcoma, squamous cell carcinoma [ see Warnings and Precautions (5.12) ]. Skin and Subcutaneous Tissue Disorders: Hypersensitivity [ see Warnings and Precautions (5.14)]

FDA lists 5 drug label records with FINGOLIMOD as the active ingredient. The most common dosage forms and the manufacturers with the most records are summarised below; strengths, pack sizes and inactive ingredients can still differ between apparently similar products.

2 FDA recall record(s) match this product name or manufacturer. A match means the firm or product name appears in the enforcement report; confirm lot numbers and dates against the official FDA notice before acting.

What is Fingolimod used for?
1 INDICATIONS AND USAGE Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod Capsules are sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of …

Who makes Fingolimod?
Novadoz Pharmaceuticals LLC is the labeler of record for Fingolimod. 5 FDA label records share the active ingredient FINGOLIMOD, so generic and branded versions may come from different companies; the manufacturer named on your pack is the one that matters for any enquiry.

What form does Fingolimod come in?
administered by oral. Strengths and pack sizes vary by label, so compare the NDC on your pack with the identifier listed on this page.

Is Fingolimod prescription or over-the-counter?
The FDA label for this product is recorded as human prescription drug. Marketing status can differ between strengths and countries, so check the dispensing rules where you live.

Are there other products containing FINGOLIMOD?
Yes. 5 FDA drug label records list FINGOLIMOD as the active ingredient. Products with the same active ingredient can usually be substituted only when a prescriber or pharmacist confirms it is appropriate.

Has Fingolimod been recalled?
2 FDA recall record(s) match this product name or manufacturer. Review the recall and safety notices section on this page and confirm lot numbers against the official FDA enforcement report.

Where does this information come from?
All content is reproduced from FDA Structured Product Labelling data via openFDA. It is provided for identification and reference only and is not medical advice.